Head-To-Head Contrast: Trident Brands (OTCMKTS:TDNT) vs. Cytosorbents (NASDAQ:CTSO)

Trident Brands (OTCMKTS:TDNT) and Cytosorbents (NASDAQ:CTSO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, profitability, risk, analyst recommendations, dividends and institutional ownership.

Profitability

This table compares Trident Brands and Cytosorbents’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trident Brands	N/A	N/A	N/A
Cytosorbents	-22.12%	-150.53%	-32.75%

Analyst Recommendations

This is a summary of current recommendations for Trident Brands and Cytosorbents, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trident Brands	0	0	0	0	0.00
Cytosorbents	1	1	1	0	2.00

Cytosorbents has a consensus price target of $5.38, indicating a potential upside of 765.54%. Given Cytosorbents’ stronger consensus rating and higher possible upside, analysts plainly believe Cytosorbents is more favorable than Trident Brands.

Valuation and Earnings

This table compares Trident Brands and Cytosorbents”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trident Brands	N/A	N/A	N/A	N/A	N/A
Cytosorbents	$37.06 million	1.05	-$8.20 million	($0.13)	-4.78

Trident Brands has higher earnings, but lower revenue than Cytosorbents.

Volatility & Risk

Trident Brands has a beta of -3.98, suggesting that its share price is 498% less volatile than the S&P 500. Comparatively, Cytosorbents has a beta of 1.47, suggesting that its share price is 47% more volatile than the S&P 500.

Institutional & Insider Ownership

32.9% of Cytosorbents shares are owned by institutional investors. 33.9% of Trident Brands shares are owned by insiders. Comparatively, 6.6% of Cytosorbents shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Cytosorbents beats Trident Brands on 6 of the 10 factors compared between the two stocks.

About Trident Brands

Trident Brands Incorporated, together with its subsidiaries, focuses on developing branded consumer products and ingredients in the nutritional supplement, life sciences, and food and beverage categories in the United States and Canada. The company develops, markets, and sells a portfolio of DHA supplements under the Brain Armor brand. It also holds various banking facilities; and licenses associated with the manufacturing, importation, and sale of natural health and nutrition products. The company was formerly known as Sandfield Ventures Corp. and changed its name to Trident Brands Incorporated in July 2013. Trident Brands Incorporated was incorporated in 2007 and is based in Boca Raton, Florida.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.